The goal of this clinical trial is to evaluate effectiveness of using e-cigarettes as harm reduction strategy for smoking cessation and decreasing risk of diseases in heavy smokers. The main questions it aims to answer are: * Is there any effectiveness of using E-cigarette as a harm reduction strategy for smoking cessation? * what are the impacts of using E-cigarette on respiratory function and risk of COPD? * Assess the exposure to harmful and potential harmful constituents (HPHCs) of using E-cigarette Participants will be randomized into a 6 months single-center, open label trial comparing study outcomes among 2 arms: health counselling, E-cigarette + health counselling. The EC arm will receive EC for 1 month. All 2 arms will receive health counselling from a licensed mental health counselor. After baseline, participants will report their use of combustible cigarette in both arms and EC use in the EC arm every day via online questionnaire in Wechat for behavioral monitoring. If there is a comparison group: Researchers will compare health counselling group to see if E-cigarrette intervention is an effective way to stop smoking, and if there any change in respiratory function and change in exposure to harmful and potential harmful constituents (HPHCs).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Ad libitum use of electronic cigarettes for 1 month
Health Counselling from a licensed mental health counselor
7-day point prevalence abstinence
The effectiveness of smoking cessation with intervention
Time frame: 1 month
Score of COPD-SQ questionnaire
self-reported score of COPD-SQ questionnaire
Time frame: 1 month
Score of COPD-PS questionnaire
self-reported score of COPD-PS questionnaire
Time frame: 1 month
Score of mMRC scale
self-reported score of modified Medical Research Council scale
Time frame: 1 month
Score of CAT questionnaire
self-reported score of COPD Assessment Test
Time frame: 1 month
%ratio of FEV1/FVC
the proportion of a person's vital capacity that are able to expire in the first second of forced expiration (FEV1) to the full, forced vital capacity (FVC).
Time frame: 1 month
Concentration of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL)
Concentration of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in urine
Time frame: 1 month
Concentration of 3-Hydroxypropyl- mercapturic acid (3-HPMA)
Concentration of 3-Hydroxypropyl- mercapturic acid (3-HPMA) in urine
Time frame: 1 month
Concentration of 2-Cyanoethylmercaturic acid (CEMA)
Concentration of 2-Cyanoethylmercaturic acid (CEMA) in urine
Time frame: 1 month
Concentration of S-phenylmercapturic Acid (S-PMA)
Concentration of S-phenylmercapturic Acid (S-PMA) in urine
Time frame: 1 month
Concentration of 3-Hydroxy-1-methylpropyl-mercapturic acid (3-HMPMA)
Concentration of 3-Hydroxy-1-methylpropyl-mercapturic acid (3-HMPMA) in urine
Time frame: 1 month
Concentration of N-nitrosonornicotine (NNN)
Concentration of N-nitrosonornicotine (NNN) in urine
Time frame: 1 month
Concentration of S-benzyl-mercapturic acid (S-BMA)
Concentration of S-benzyl-mercapturic acid (S-BMA) in urine
Time frame: 1 month
Concentration of cotinine
Concentration of cotinine in urine
Time frame: 1 month
Concentration of Trans-3-Hydroxy Cotinine (TNE-2)
Concentration of Trans-3-Hydroxy Cotinine (TNE-2) in urine
Time frame: 1 month
Concentration of total Nicotine equivalent
Concentration of total Nicotine equivalent in urine
Time frame: 1 month
Concentration of formic acid
Concentration of formic acid in urine
Time frame: 1 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.